BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension

BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension

Inhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease in the United States. Studies have confirmed the robust benefits and safety of nebulized inhaled treprostinil, but it requires a time investment...

Full description

Bibliographic Details
Main Authors: Bajwa, A.A (Author), Burger, C.D (Author), Deng, C. (Author), Desai, S.V (Author), Eggert, M.S (Author), El-Kersh, K.A (Author), Fisher, M.R (Author), Johri, S. (Author), Joly, J.M (Author), Mehta, J. (Author), Miceli, M. (Author), Palevsky, H.I (Author), Ramani, G.V (Author), Restrepo-Jaramillo, R. (Author), Sahay, S. (Author), Shah, T.G (Author), Shapiro, S.M (Author), Smith, P. (Author), Spikes, L.A (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2022
Subjects:
dry powder inhaler
PAH-SYMPACT
pharmacokinetics
quality of life
treprostinil
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items